Literature DB >> 19501956

Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.

Eduardo Huarte1, Jan Fisher, Mary Jo Turk, Diane Mellinger, Cathy Foster, Benita Wolf, Kenneth R Meehan, Camilo E Fadul, Marc S Ernstoff.   

Abstract

Although T central memory cells have been described as the most effective T-cell subtype against tumor growth, little is known about the requirements needed for their optimal ex vivo generation. Hence, our goal is to establish a protocol that will lead to consistent ex vivo generation of lymphocytes skewed toward a central memory phenotype. Antigen-specific T-cell lines were generated by ex vivo stimulation with Class-I and Class-II melanoma peptide pulsed dendritic cells in the presence of either IL-2 or IL-15 plus IL-21. Tumor specific lymphocytes of both central memory and effector characteristics were consistently generated from healthy donors and melanoma patients. IL15/IL21 cultures result in a cell population with a lower proportion of CD4(+)CD25(high)FoxP3(+) regulatory cells and higher number of CD8(+) and CD56(+) cells, and consequently render a higher yield of cells with a greater cytolytic activity and IFN-gamma production against melanoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501956      PMCID: PMC3772508          DOI: 10.1016/j.canlet.2009.05.003

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  51 in total

1.  Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes.

Authors:  N Manjunath; P Shankar; J Wan; W Weninger; M A Crowley; K Hieshima; T A Springer; X Fan; H Shen; J Lieberman; U H von Andrian
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

2.  CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.

Authors:  A Ribas; L H Butterfield; S N Amarnani; V B Dissette; D Kim; W S Meng; G A Miranda; H J Wang; W H McBride; J A Glaspy; J S Economou
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

3.  Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression.

Authors:  M J Pittet; D E Speiser; D Valmori; J C Cerottini; P Romero
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

4.  A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard M Sherry; Francesco M Marincola; Susan F Leitman; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Azam Nahvi; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

5.  CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.

Authors:  G Zeng; X Wang; P F Robbins; S A Rosenberg; R F Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

6.  Control of homeostasis of CD8+ memory T cells by opposing cytokines.

Authors:  C C Ku; M Murakami; A Sakamoto; J Kappler; P Marrack
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

7.  Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy.

Authors:  M Oelke; U Moehrle; J L Chen; D Behringer; V Cerundolo; A Lindemann; A Mackensen
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

8.  Identification of helper T-cell epitopes that encompass or lie proximal to cytotoxic T-cell epitopes in the gp100 melanoma tumor antigen.

Authors:  H Kobayashi; J Lu; E Celis
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

Review 9.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

10.  Enhancing immunogenicity of a CTL epitope from carcinoembryonic antigen by selective amino acid replacements.

Authors:  Eduardo Huarte; Pablo Sarobe; Jun Lu; Noelia Casares; Juan José Lasarte; Javier Dotor; Marta Ruiz; Jesús Prieto; Esteban Celis; Francisco Borrás-Cuesta
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

View more
  17 in total

1.  Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.

Authors:  Aki Furusawa; John Reiser; Kavitha Sadashivaiah; Haley Simpson; Arnob Banerjee
Journal:  J Immunother       Date:  2018 Feb/Mar       Impact factor: 4.456

Review 2.  T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics.

Authors:  Z Wu; N V Cheung
Journal:  Pharmacol Ther       Date:  2017-08-20       Impact factor: 12.310

3.  Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Authors:  Amanda Contreras; Siddhartha Sen; Andrew J Tatar; David A Mahvi; Justin V Meyers; Prakrithi Srinand; Marulasiddappa Suresh; Clifford S Cho
Journal:  Cancer Immunol Immunother       Date:  2016-03-24       Impact factor: 6.968

4.  Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study.

Authors:  Jeong-Hoon Lee; Won Young Tak; Yoon Lee; Min-Kyu Heo; Jae-Sung Song; Hak-Yeop Kim; Soo Young Park; Si Hyun Bae; Joon Hyeok Lee; Jeong Heo; Ki-Hwan Kim; Yong-Soo Bae; Yoon Jun Kim
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

Review 5.  Redirecting the immune response: role of adoptive T cell therapy.

Authors:  Anna Mondino; Valérie Dardalhon; Rodrigo Hess Michelini; Severine Loisel-Meyer; Naomi Taylor
Journal:  Hum Gene Ther       Date:  2010-05       Impact factor: 5.695

Review 6.  Immunomodulatory cytokines as therapeutic agents for melanoma.

Authors:  Courtney Nicholas; Gregory B Lesinski
Journal:  Immunotherapy       Date:  2011-05       Impact factor: 4.196

7.  T cell receptor-engineered T cells to treat solid tumors: T cell processing toward optimal T cell fitness.

Authors:  Cor H J Lamers; Sabine van Steenbergen-Langeveld; Mandy van Brakel; Corrien M Groot-van Ruijven; Pascal M M L van Elzakker; Brigitte van Krimpen; Stefan Sleijfer; Reno Debets
Journal:  Hum Gene Ther Methods       Date:  2014-12       Impact factor: 2.396

Review 8.  Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer.

Authors:  Natasha M Fewkes; Crystal L Mackall
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

Review 9.  Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12.

Authors:  Theofanis Floros; Ahmad A Tarhini
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

10.  Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia.

Authors:  Philipp Koehler; Patrick Schmidt; Andreas A Hombach; Michael Hallek; Hinrich Abken
Journal:  Adv Hematol       Date:  2011-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.